142 related articles for article (PubMed ID: 12429213)
1. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red.
Sakamoto M; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Mizusawa H; Hirai S
Exp Neurol; 2002 Sep; 177(1):88-94. PubMed ID: 12429213
[TBL] [Abstract][Full Text] [Related]
2. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods.
Uchihara T; Nakamura A; Mochizuki Y; Hayashi M; Orimo S; Isozaki E; Mizutani T
Acta Neuropathol; 2005 Sep; 110(3):255-60. PubMed ID: 16003542
[TBL] [Abstract][Full Text] [Related]
3. Progressive accumulation of ubiquitin and disappearance of alpha-synuclein epitope in multiple system atrophy-associated glial cytoplasmic inclusions: triple fluorescence study combined with Gallyas-Braak method.
Sakamoto M; Uchihara T; Nakamura A; Mizutani T; Mizusawa H
Acta Neuropathol; 2005 Oct; 110(4):417-25. PubMed ID: 16133540
[TBL] [Abstract][Full Text] [Related]
4. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining.
Gómez-Tortosa E; Newell K; Irizarry MC; Sanders JL; Hyman BT
Acta Neuropathol; 2000 Apr; 99(4):352-7. PubMed ID: 10787032
[TBL] [Abstract][Full Text] [Related]
5. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62.
Kuusisto E; Parkkinen L; Alafuzoff I
J Neuropathol Exp Neurol; 2003 Dec; 62(12):1241-53. PubMed ID: 14692700
[TBL] [Abstract][Full Text] [Related]
6. Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissues.
D'Andrea MR; Ilyin S; Plata-Salaman CR
Neurosci Lett; 2001 Jun; 306(3):137-40. PubMed ID: 11406314
[TBL] [Abstract][Full Text] [Related]
7. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
Wakabayashi K
Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
[TBL] [Abstract][Full Text] [Related]
8. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies.
Ishizawa T; Mattila P; Davies P; Wang D; Dickson DW
J Neuropathol Exp Neurol; 2003 Apr; 62(4):389-97. PubMed ID: 12722831
[TBL] [Abstract][Full Text] [Related]
9. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.
Lippa CF; Fujiwara H; Mann DM; Giasson B; Baba M; Schmidt ML; Nee LE; O'Connell B; Pollen DA; St George-Hyslop P; Ghetti B; Nochlin D; Bird TD; Cairns NJ; Lee VM; Iwatsubo T; Trojanowski JQ
Am J Pathol; 1998 Nov; 153(5):1365-70. PubMed ID: 9811326
[TBL] [Abstract][Full Text] [Related]
10. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
11. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease.
Lippa CF; Schmidt ML; Lee VM; Trojanowski JQ
Arch Neurol; 2001 Nov; 58(11):1817-20. PubMed ID: 11708989
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.
Mattila PM; Rinne JO; Helenius H; Dickson DW; Röyttä M
Acta Neuropathol; 2000 Sep; 100(3):285-90. PubMed ID: 10965798
[TBL] [Abstract][Full Text] [Related]
14. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
15. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
Yamamoto S; Fukae J; Mori H; Mizuno Y; Hattori N
Neurosci Lett; 2006 Apr; 396(3):187-91. PubMed ID: 16386370
[TBL] [Abstract][Full Text] [Related]
16. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
17. Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment.
Takeda A; Hashimoto M; Mallory M; Sundsumo M; Hansen L; Sisk A; Masliah E
Lab Invest; 1998 Sep; 78(9):1169-77. PubMed ID: 9759660
[TBL] [Abstract][Full Text] [Related]
18. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
19. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
20. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.
Giasson BI; Jakes R; Goedert M; Duda JE; Leight S; Trojanowski JQ; Lee VM
J Neurosci Res; 2000 Feb; 59(4):528-33. PubMed ID: 10679792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
